MARKET

PPBT

PPBT

Purple Biotech Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.480
0.000
0.00%
After Hours: 2.550 +0.07 +2.82% 18:45 06/24 EDT
OPEN
2.470
PREV CLOSE
2.480
HIGH
2.574
LOW
2.460
VOLUME
26.61K
TURNOVER
0
52 WEEK HIGH
5.82
52 WEEK LOW
2.430
MARKET CAP
44.35M
P/E (TTM)
-0.1186
1D
5D
1M
3M
1Y
5Y
Purple Biotech stock falls amid interim phase 1 data of NT219 in advanced tumors
Purple Biotech (NASDAQ:PPBT) reported interim data from a phase 1 trial of NT219 as a standalone therapy to treat adults with advanced solid tumors. The study included patients with colorectal, pancreatic
Seekingalpha · 05/27 13:00
Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile
A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer REHOVOT, Israel, May 27, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a cli...
GlobeNewswire · 05/27 11:15
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 05/26 22:13
Celularity, Purple Biotech top healthcare gainers; Baudax Bio, Doximity lead losers' pack
Gainers: Celularity CELU +10%. Purple Biotech (PPBT) +8%. BioSig Technologies (BSGM) +4%. Concert Pharmaceuticals (CNCE) +4%. Molecular Partners (MOLN) +4%. Losers: Baudax Bio BXRX -28%. Doximity DOCS -9%. Radius Health (RDUS) -7%. NextGen Healthcare (NXGN...
Seekingalpha · 05/18 14:05
Purple Biotech initiates phase 2 study for its antibody CM24 in pancreatic cancer patients
Purple Biotech (NASDAQ:PPBT) on Wednesday initiated the phase 2 portion of its ongoing study of monoclonal antibody CM24, which has the potential to treat multiple cancers. The mid-stage portion of
Seekingalpha · 05/18 13:45
BRIEF-Purple Biotech Announces The Initiation Of Phase 2 Study For Cm24 In 2L Pdac Patients
reuters.com · 05/18 13:32
Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients
Decision based on positive interim Phase 1b data in pancreatic ductal adenocarcinoma (PDAC)REHOVOT, Israel, May 18, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company focused on d...
GlobeNewswire · 05/18 12:18
Purple Biotech GAAP EPS of $0.41
Purple Biotech press release (NASDAQ:PPBT): Q1 GAAP EPS of $0.41. Cash and cash equivalents of $23.54M
Seekingalpha · 05/12 12:53
More
No Data
Learn about the latest financial forecast of PPBT. Analyze the recent business situations of Purple Biotech Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PPBT stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.
High25.00
Average25.00
Low25.00
Current 2.480
EPS
Actual
Estimate
-6.55-4.91-3.28-1.64
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 33
Institutional Holdings: 466.62K
% Owned: 2.61%
Shares Outstanding: 17.88M
TypeInstitutionsShares
Increased
1
17.96K
New
3
77.06K
Decreased
4
34.39K
Sold Out
3
662.59K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/Director
Eric Rowinsky
Chief Executive Officer/Director
Itzhak Israel
Deputy Chief Executive Officer/Chief Financial Officer
Gil Efron
Vice President - Business Development
Gil Ben-Menachem
General Counsel/Secretary
Avraham Ben-Tzvi
Other
Yisrael Gewirtz
Other
Bertrand Liang
Other
Hadas Reuveni
Other
Michael Schickler
Director
Robert Gagnon
Director
Suzana Nahum-Zilberberg
Director
Simcha Rock
Independent Director
Ido Agmon
Independent Director
Steven Steinberg
Independent Director
Revital Stern-Raff
Independent Director
Ran Tzror
Independent Director
Arie Weber
No Data
No Data
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Webull offers kinds of Purple Biotech Ltd stock information, including NASDAQ:PPBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PPBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PPBT stock methods without spending real money on the virtual paper trading platform.